Insulet Co. (NASDAQ:PODD) Receives $306.53 Consensus PT from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have been assigned a consensus recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $306.53.

Several research firms have recently commented on PODD. Sanford C. Bernstein reiterated an “outperform” rating on shares of Insulet in a report on Friday. Oppenheimer raised their price objective on shares of Insulet from $312.00 to $324.00 and gave the stock an “outperform” rating in a research report on Friday, May 9th. Raymond James reissued an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Barclays increased their price target on shares of Insulet from $234.00 to $266.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 30th. Finally, StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th.

Insiders Place Their Bets

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP John W. Kapples sold 5,278 shares of the company’s stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the transaction, the senior vice president now owns 23,180 shares of the company’s stock, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insulet

Institutional investors and hedge funds have recently bought and sold shares of the stock. Avanza Fonder AB purchased a new position in Insulet during the 4th quarter worth approximately $1,760,000. Sax Wealth Advisors LLC boosted its holdings in shares of Insulet by 101.3% in the fourth quarter. Sax Wealth Advisors LLC now owns 3,044 shares of the medical instruments supplier’s stock valued at $795,000 after acquiring an additional 1,532 shares during the period. Arkadios Wealth Advisors boosted its holdings in shares of Insulet by 59.9% in the fourth quarter. Arkadios Wealth Advisors now owns 2,056 shares of the medical instruments supplier’s stock valued at $537,000 after acquiring an additional 770 shares during the period. Diversify Wealth Management LLC boosted its holdings in shares of Insulet by 51.2% in the fourth quarter. Diversify Wealth Management LLC now owns 2,762 shares of the medical instruments supplier’s stock valued at $751,000 after acquiring an additional 935 shares during the period. Finally, Trust Asset Management LLC purchased a new stake in Insulet in the 4th quarter valued at $211,000.

Insulet Trading Up 0.5%

Shares of Insulet stock opened at $327.47 on Friday. The firm’s 50-day moving average price is $267.35 and its 200 day moving average price is $267.99. Insulet has a twelve month low of $170.67 and a twelve month high of $329.00. The firm has a market capitalization of $23.05 billion, a PE ratio of 56.56, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. The firm had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same period last year, the firm posted $0.73 earnings per share. On average, sell-side analysts predict that Insulet will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.